CTOs on the Move

Napp Technologies

www.napptech.com

 
Napp Technologies is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.napptech.com
  • 401 Hackensack Ave
    Hackensack, NJ USA 07601
  • Phone: 201.843.4664

Executives

Name Title Contact Details

Similar Companies

Talia Technology (Marco Ophthalmic)

Talia Technology (Marco Ophthalmic Inc.) is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Envivo

Envivo is a Watertown, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eupraxia Pharmaceuticals

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.

Civica Rx

Civica Rx was created in late 2018 to secure the supply of important medicines hospitals use every day. As of Q2 2023, we have provided over 125 million units of essential medicines to hospitals, enough to help treat over 50 million patients. Recently, we announced we will manufacture and distribute affordable medications for consumers in an outpatient/retail setting, including affordable insulin. Insulin is an exciting project as we are partnering with nearly every corner of the diabetes ecosystem to bring low-cost insulin to people living with diabetes at no more than $30 a vial and no more than $55 for a pack of five pre-filled pens, regardless of insurance status.

Synergy Pharmaceuticals

Synergy is a gastrointestinal-focused biopharmaceutical company committed to science-based innovation, providing novel treatment options for patients and healthcare providers, rewarding opportunities for our employees, and creating exceptional value for our shareholders.